Angiotensin II Inhibits Insulin Binding to Endothelial Cells by Oh, Su-Jin et al.
D I A B E T E S  &  M E T A B O L I S M   J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2011 Korean Diabetes Association  http://e-dmj.org
Diabetes Metab J 2011;35:243-247
Angiotensin II Inhibits Insulin Binding to Endothelial 
Cells
Su-Jin Oh
1, Won-Chul Ha
1, Jee-In Lee
1, Tae-Seo Sohn
1, Ji-Hyun Kim
1, Jung-Min Lee
1, Sang- Ah Chang
1, Oak-Kee Hong
2, 
Hyun-Shik Son
1
1Division of Endocrinology and Metabolism, Department of Internal Medicine, The Catholic University of Korea College of Medicine, 
2Catholic Research Institutes of Medical Science, The Catholic University of Korea, Seoul, Korea
Background:  Insulin-mediated glucose uptake in insulin target tissues is correlated with interstitial insulin concentration, rath-
er than plasma insulin concentration. Therefore, insulin delivery to the interstitium of target tissues is very important, and the 
endothelium may also play an important role in the development of insulin resistance. 
Methods:  After treating bovine aortic endothelial cells with angiotensin II (ATII), we observed the changes in insulin binding 
capacity and the amounts of insulin receptor (IR) on the cell membranes and in the cytosol.
Results:  After treatment of 10
-7M ATII, insulin binding was decreased progressively, up to 60% at 60 minutes (P<0.05). ATII re-
ceptor blocker (eprosartan) dose dependently improved the insulin binding capacity which was reduced by ATII (P<0.05). At 
200 μM, eprosartan fully restored insulin binding capacity, althogh it resulted in only a 20% to 30% restoration at the therapeutic 
concentration. ATII did not affect the total amount of IR, but it did reduce the amount of IR on the plasma membrane and in-
creased that in the cytosol.
Conclusion:  ATII decreased the insulin binding capacity of the tested cells. ATII did not affect the total amount of IR but did 
decrease the amount of IR on the plasma membrane. Our data indicate that ATII decreases insulin binding by translocating IR 
from the plasma membrane to the cytosol. The binding of insulin to IR is important for insulin-induced vasodilation and tran-
sendothelial insulin transport. Therefore, ATII may cause insulin resistance through this endothelium-based mechanism.
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INTRODUCTION
The actions of insulin on glucose metabolism are to increase 
glucose uptake in peripheral insulin target tissues (skeletal mus-
cle and adipose tissue) and to inhibit glucose production by the 
liver. Before insulin can act on target tissues, it has to be secret-
ed from pancreatic β-cells and transported from the blood across 
the endothelium to the interstitia of target tissues. Many stud-
ies have demonstrated that insulin-mediated glucose disposal 
increases progressively in a time- and dose-dependent man-
ner; however, this transport is strongly correlated with lymphat-
ic than plasma insulin concentration [1]. Thus, transcapillary 
insulin transport may be a rate-limiting step in insulin action, 
and impairment of the processes involved may contribute to 
insulin resistance. 
  It is believed that two steps are needed to deliver insulin to 
target tissues. The first step is the relaxation of terminal arteri-
oles within target organs (capillary recruitment), and the sec-
ond is the insulin transport to the interstitium across the endo-
thelium. It is well known that insulin increases its own delivery 
to target organs by increasing nitric oxide (NO) production, 
due to activation of endothelial NO synthase (eNOS) through 
Original Article
doi: 10.4093/dmj.2011.35.3.243
pISSN 2233-6079 · eISSN 2233-6087244
Oh S-J, et al.
Diabetes Metab J 2011;35:243-247 http://e-dmj.org
the PI3 kinase-Akt signal pathway [2]. However, the mechanism 
for insulin transport across the endothelium remains unclear. 
Receptor mediated transcytosis [3-5] and passive diffusion [6, 
7] have been suggested as possible mechanisms. It is generally 
accepted that insulin is transported by receptor-mediated tran-
scytosis, and that insulin receptor (IR) and insulin-like growth 
factor-1 receptor (IGF-1R) play an important role in this pro-
cess. 
  The purpose of this study is to examine whether angiotensin 
II (ATII), which is a known substance involved in the increase 
in insulin resistance, inhibits insulin binding on bovine aortic 
endothelial cells (BAECs). Insulin binding is considered as an 
initially required process for insulin signaling and receptor-me-
diated transcytosis on endothelium. Therefore, inhibition of 
insulin binding on endothelial cells may reduce the delivery of 
insulin to target tissues, causing insulin resistance.  
METHODS
Materials 
Bovine insulin, ATII and eprosartan were purchased from Sig-
ma–Aldrich (St. Louis, MO, USA). Anti-insulin receptor beta 
subunit (Anti-IRβ) was from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA, USA). 
Cell culture
The bovine aortic endothelial cells (Lonza, Walkersville, MD, 
USA) were cultured in DMEM medium supplemented with 
10% fetal bovine serum (FBS), 100 units/mL penicillin G and 
0.1 mg/mL streptomycin. Cells were maintained at 37°C in hu-
midified air and 5% CO2. The medium was replaced three times 
a week. The cells were separated 5 to 10 times for use in the pres-
ent experiments. 
Insulin binding study
Insulin binding was studied using a modification of the methods 
of Kaiser et al. [8]. The cells were plated into dishes with DMEM 
containing 0.5% FBS for 24 hours and incubated at 37°C with 
Tris-Hepes binding buffer (50 mM Tris, 50 mM Hepes, 10 mM 
MgC12, 2 mM EDTA, 10 mM dextrose, 10 mM CaC12, 50 mM 
NaCl, 5 mM KCl, 0.5% crystalline BSA, pH 7.8) and [
125I]-in-
sulin (0.5 μCi/well) for 0, 10, 20, 30, 60, and 90 minutes. To in-
vestigate whether insulin binding was affected by ATII, we add-
ed 10
-7M ATII with or without ATII receptor blocker (eprosar-
tan, 0.02, 0.2, 2, 20, and 200 μM) to the cells. After incubation, 
the supernatant was removed and the cells were immediately 
washed three times with 2 mL ice-cold phosphate-buffered sa-
line (PBS). The cells were then treated with 1 mL 0.1 N NaOH 
to detach them from the dishes. The radioactivity of the insu-
lin binding to the cells was counted in a Gamma counter (Pack-
ard Bioscience Company, Downers Grove, IL, USA). The insulin 
binding capacity was calculated using the following formula.
Insulin binding capacity=  (radioactivity in cells/total radio-
activity)×100
Protein extraction and Western blot analysis 
The cells were lysed with ice-cold lysis buffer (150 mM NaCl, 
50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 1% NP-40, 10 mM NaF, 
1 mM Na3VO4, 10 mM sodium pyrophosphate, 1 mM PMSF, 
10 mg/mL aprotinin, 10 mg/mL leupeptin, and 0.1 mg/mL soy-
bean inhibitor) and centrifuged at 14,000 rpm for 10 minutes 
at 4°C. Extracted proteins were denatured at 95°C for 3 minutes 
in 2× SDS sample buffer containing 125 mM Tris, 4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol and 0.2% bromophenol blue. 
The proteins (50 μg) were fractionated in 10% SDS-PAGE at 
20 mA for 2 to 5 hours and were transferred to nitrocellulose 
membrane in transfer buffer (25 mM Tris, pH 8.3, 192 mM 
glycine, 20% methanol) at 250 mA for 1 hour at 4°C. Follow-
ing transfer, the membranes were blocked with 5% fat-free dry 
milk for 1 hour in Tris-buffered saline (TBS; 25 mM Tris-HCl, 
pH 7.6, and 150 mM NaCl) containing 0.1% Tween 20 (TBS-
T). Primary antibodies for IRβ were used at 1:1,000 dilutions 
in TBS-T containing 5% fat-free dry milk at 4°C. Membrane 
were exposed to secondary antibodies conjugated with horse-
radish peroxidase (Calbiochem, San Diego, CA, USA) diluted 
1:1,000 in 5% fat-free dry milk in TBS-T at room temperature 
for 1 hour. Staining was detected with an enhanced chemilu-
minescence kit (Santa Cruz Biotechnology Inc.).
Subcellular fractionation
Membrane and cytosol proteins were separated and extracted 
using the MEM-PER mammalian membrane protein extrac-
tion kit (Pierce Chemical Co., Rockford, IL, USA) according 
to the manufacturer’s recommendations. 
Statistical analysis 
All experimental results are described as the means±SEM. Sta-
tistical significance was determined using Student’s t-test, and 
one-way ANOVA, and P values of less than 0.05 was consid-
ered significant.245
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RESULTS
Effects of ATII on insulin binding capacity
As shown in Fig. 1, after treatment with insulin, the insulin 
binding capacity was increased over time and reached a peak 
at 20 minutes and a plateau at 30 minutes. When adding 10
-7M 
ATII, insulin binding was decreased progressively, up to 60% at 
60 minutes. These data show that ATII inhibits insulin binding 
on bovine aortic endothelial cell. To determine whether ARB 
restores this effect, we pretreated the cells with eprosartan (0.02, 
0.2, 2, 20, and 200 μM) for 30 minutes, then added [
125I]-insu-
lin (0.5 μCi/well) and ATII (10
-7M) for 60 minutes. As shown 
in Fig. 2, eprosartan dose dependently improved the insulin 
binding capacity which was reduced by ATII. At 200 μM, epro-
sartan fully restored insulin binding capacity, although only a 
20% to 30% restoration was observed at the therapeutic con-
centration.
Effects of insulin and ATII on the amounts of IR
To determine whether insulin and ATII affect the amount of 
IR, we treated bovine aortic endothelial cells with 10
-7M insu-
lin and 10
-7M ATII. As shown in Fig. 3A, neither insulin nor 
ATII affected the total amounts of IRβ. Instead, ATII reduced 
the amount of IRβ on the cell membrane and increased that in 
the cytosol. These data suggest that ATII translocates insulin 
receptor proteins from the cell membrane to the cytosol and 
thereby inhibits insulin binding with IR on endothelial cells. To 
determine whether this effect of ATII is offset by ARB, we pre-
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Fig. 1.  The effect of angiotensin II (ATII) on insulin binding. 
Bovine aortic endothelial cells were pretreated with 10
-7M ATII, 
then subjected to [
125I]-insulin (0.5 μCi/well). Binding assays 
were performed as described in Methods. 
aP<0.05; control vs. 
ATII.
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Fig. 2.  The effect of angiotensin receptor blocker (eprosartan) 
on insulin binding. Bovine aortic endothelial cells were prein-
cubated with eprosartan (0.02, 0.2, 2, 20, and 200 μM) for 30 
minutes, and then [
125I]-insulin (0.5 μCi/well) and angiotensin 
II (ATII) (10
-7M) were added for 60 minutes. Binding assays 
were performed as described in Methods. 
aP<0.05; ATII vs. 
eprosartan.
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Fig. 3.  The changes in the amounts of insulin receptor beta subunit (IRβ) on the plasma membrane and in the cytosol due to 
treatment with insulin and angiotensin II (ATII). (A) Bovine aortic endothelial cells were treated with 10
-7M insulin and 10
-7M 
ATII. (B) Bovine aortic endothelial cells were preincubated with eprosartan (200 μM) for 30 minutes, then 10
-7M insulin and 10
-
7M ATII were added. The amounts of IRβ were measured using Western blotting. Membrane and cytosol proteins were separated 
and extracted using the MEM-PER mammalian membrane protein extraction kit. 
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treated cells with 200 μM eprosartan for 30 minutes and added 
10
-7M insulin and 10
-7M ATII. As shown in Fig. 3B, eprosartan 
inhibited the translocation of IRβ by ATII.
DISCUSSION
Insulin-mediated glucose uptake is correlated with interstitial 
insulin concentration in insulin target tissues rather than with 
plasma concentration [1]. In human studies, interstitial insulin 
concentrations estimated through microdialysis are reported to 
be only 40% to 60% of simultaneous measured plasma concen-
trations and the time kinetics of insulin are slower in the inter-
stitial fluid than they are in plasma [9-11]. Several studies have 
suggested that the maximal interstitial insulin concentration is 
similar in the normal and insulin-resistant states, but transcap-
illary insulin transport is delayed in the insulin-resistant state 
[10,12]. Therefore, transcapillary insulin transport may be im-
portant for insulin action, and the endothelium may play an 
important barrier role in the development of insulin resistance.   
  It is thought that insulin delivery to target tissues is achieved 
in a two-step process. The first step is the relaxation of terminal 
arterioles within target organs (capillary recruitment), and the 
second is insulin transport to the interstitium across the endo-
thelium. 
  It is well known that insulin increases its own delivery to tar-
get organs by increasing the production of NO in endothelium. 
When insulin on endothelium binds insulin receptor, eNOS is 
activated via phosphorylation at Ser
1177 through the PI3kinase–
Akt signal pathway, resulting in increased NO production [2]. 
NO diffuses into the adjacent vascular smooth muscle cells and 
causes vasodilation of terminal arterioles and capillary recruit-
ment [2]. 
  Endothelia from different tissues have various structures 
and permeability [13]. The endothelium within skeletal mus-
cle, which contributes to most of the peripheral glucose uptake, 
is relative tight and makes paracellular transport of most mac-
romolecules (including insulin) difficult [13]. The mechanism 
for insulin transport across the endothelium in skeletal muscle 
is not yet known. Some in vitro studies have suggested that in-
sulin is transported by receptor mediated transcytosis [3-5]. On 
the other hand, in vivo studies suggest that insulin is transport-
ed by passive diffusion because this process does not appear to 
be saturable [6,7]. But now, it is generally accepted that insulin 
is transported by receptor-mediated transcytosis (in relation 
to the formation of caveolae), and that IR and IGF-1R play an 
important role in this process. 
  In this study, we tried to investigate whether ATII affects in-
sulin binding on endothelial cells. Because it is thought that in-
sulin binding on the endothelium is an initial step in eNOS ac-
tivation via insulin signaling and receptor-mediated insulin 
transcytosis, the impairment of insulin binding can affect trans-
capillary insulin transport and cause insulin resistance. As shown 
in our results, ATII decreased the insulin binding capacity on 
endothelium. We observed that treatment with ATII did not 
affect the total amount of IR, although the amount of IR on the 
cell membrane was decreased and that in the cytosol was in-
creased. Various possibilities may be considered to explain these 
results, but the data indicate that ATII decreases insulin bind-
ing by decreasing the amount of IR on the cell membrane due to 
translocation of IR to the cytosol. In addition, this study showed 
that ARB improved the insulin binding capacity which was re-
duced by ATII and inhibited the translocation of IR by ATII. 
In conclusion, we think that ATII may cause insulin resistance 
through inhibiting insulin and insulin receptor binding on the 
endothelium, which may be another insulin target site which 
can cause insulin resistance through the regulation of transcap-
illary insulin transport. In addition, ARB may help to improve 
insulin resistance on the endothelium. 
  There are several limitations in our study. First, we can not 
tell whether eNOS activation or receptor-mediated transcyto-
sis is more affected by a reduction in insulin binding, eNOS. 
Several studies have suggested that ATII decreases the bioavail-
ability and production of NO in endothelium via ROS produc-
tion and inhibition of the PI3 kinase-Akt signal pathway [14-
16]. However, no study has found that ATII directly affects re-
ceptor-mediated transcytosis. Therefore, further studies are 
needed to determine if this is true. Because IGF-1R is an addi-
tional insulin binding receptor (it is more abundant in the en-
dothelium than is IR [17]) and caveolin-1 and c-Src play an im-
portant role in the formation of caveolae, it will be necessary to 
observe the changes in the total amounts of IFG-1R and cave-
olin-1 and the amounts on the plasma membrane after treat-
ment with ATII. Second, we used bovine aortic endothelial cells 
(BAECs), if we had used human capillary endothelial cell in-
stead of BAECs, the result would have been more reliable. Third, 
we used ATII as the cause of insulin resistance. To verify that 
the endothelium is an insulin target site which causes insulin 
resistance, it is necessary to examine whether other substances 
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-
6, free fatty acid, etc., which are believed to increase insulin re-247
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sistance, impair transcapillary insulin transport. 
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